NCT02911415
Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi No drug interventions Not Available Not Available completed NCT01353027
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus No drug interventions treatment 1 completed NCT01593072
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers treatment 1 withdrawn NCT00374309
Experimental Vaccine for Prevention of Ebola Virus Infection No drug interventions prevention 1 completed NCT02661464
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo prevention 3 terminated NCT00072605
Experimental Ebola Vaccine Trial No drug interventions treatment 1 completed NCT05284097
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study prevention 2 active_not_recruiting NCT02911428
Open Study of the Duration of Immunity After Vaccination With GamEvac No drug interventions Not Available Not Available completed NCT02342171
Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea No drug interventions treatment 2 / 3 completed NCT02564575
Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults No drug interventions prevention 1 completed NCT02354404
Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda No drug interventions prevention 1 completed NCT02564523
Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults prevention 2 completed NCT02378753
STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) No drug interventions prevention 2 / 3 completed NCT02598388
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo prevention 2 completed NCT02283099
Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP) No drug interventions treatment 1 completed NCT05067166
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human mAb Ansuvimab as Therapeutic or for HR PEP Not Available Not Available available NCT02041715
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802 No drug interventions treatment 1 terminated NCT02363322
Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection treatment 1 / 2 completed NCT02319772
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430 treatment 1 completed NCT01518881
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion No drug interventions treatment 1 terminated NCT02575456
A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine No drug interventions prevention 2 completed NCT03583606
A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z) prevention 1 completed NCT02891980
A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers prevention 1 completed NCT02416453
A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults treatment 2 completed NCT02287480
VSV-ZEBOV Geneva Vaccine Trial No drug interventions prevention 1 / 2 completed NCT05494801
Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III No drug interventions Not Available Not Available recruiting NCT06587503
Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses prevention 4 not_yet_recruiting NCT03576690
R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease Not Available Not Available available NCT02329054
Efficacy of Favipiravir Against Ebola (JIKI) treatment 2 completed NCT02296983
A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya. No drug interventions prevention 1 unknown_status NCT04235361
Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC No drug interventions Not Available Not Available unknown_status NCT02333578
Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment No drug interventions treatment Not Available unknown_status NCT05202288
Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers prevention 2 unknown_status NCT00997607
Evaluating an Ebola and a Marburg Vaccine in Uganda No drug interventions prevention 1 completed NCT02267109
Phase 1 Trial of Ebola Vaccine in Mali No drug interventions prevention 1 completed NCT03820739
EBOVAC-Salone Extension No drug interventions Not Available Not Available completed NCT04717830
An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease No drug interventions treatment 1 unknown_status NCT04815174
Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease No drug interventions Not Available Not Available completed NCT04822376
Prophylaxis Vaccine Antibodies Ebola prevention 2 unknown_status NCT02451891
A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z No drug interventions prevention 1 unknown_status NCT02307591
Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) treatment 2 / 3 withdrawn NCT05992480
REVIVE (Response to the Ebola Virus Vaccine) prevention 4 not_yet_recruiting NCT04250168
Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response No drug interventions Not Available Not Available terminated NCT06093646
Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda No drug interventions supportive_care Not Available recruiting NCT00605514
Ebola and Marburg Virus Vaccines No drug interventions prevention 1 completed NCT04723602
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults No drug interventions prevention 1 completed NCT05130398
Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon prevention 1 / 2 completed NCT04409405
Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola) No drug interventions Not Available Not Available completed NCT02876328
Partnership for Research on Ebola VACcinations prevention 2 completed NCT05064956
Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study) prevention 2 completed NCT04711356
Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study) prevention 2 completed NCT04186000
Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola prevention 2 completed NCT05888649
Community Preparedness for Outbreak Response and Readiness for Ebola Vaccination in Liberia No drug interventions Not Available Not Available not_yet_recruiting NCT04028349
ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo) prevention 2 completed NCT06100913
Immunology of Ebola Vaccine basic_science 2 recruiting NCT02368119
Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO) No drug interventions prevention 1 completed NCT04152486
Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC prevention 3 unknown_status NCT06126822
Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC prevention 3 not_yet_recruiting NCT02380625
Multiple Treatments for Ebola Virus Disease (EVD) treatment 1 / 2 unknown_status NCT03072030
International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi No drug interventions prevention 4 completed NCT03929757
A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants prevention 2 completed NCT04268966
An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola treatment 2 withdrawn NCT03161366
Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine No drug interventions prevention 3 completed NCT03140774
Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines No drug interventions Not Available Not Available completed NCT02658331
Evaluation of the FilmArray BioThreat-E Test No drug interventions Not Available Not Available completed NCT02401373
A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China. No drug interventions prevention 1 completed NCT02326194
A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults. No drug interventions prevention 1 completed NCT02509494
Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo prevention 3 completed NCT02533791
A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization No drug interventions prevention 1 completed NCT03098862
PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response No drug interventions Not Available Not Available completed NCT04906629
INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees No drug interventions prevention 1 completed NCT03462004
Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein No drug interventions prevention 1 suspended NCT02718469
Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults No drug interventions prevention 1 completed NCT02495246
A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV prevention 1 completed NCT02485912
Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination No drug interventions prevention 1 completed NCT02662855
Efficacy of Favipiravir Against Severe Ebola Virus Disease treatment 2 completed NCT02431923
Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up No drug interventions Not Available Not Available completed